Neuropathy Pain Treatment Industry – Increasing Mergers and Acquisitions would Lead to Further Consolidation

Research analysts forecast the global neuropathy pain treatment market to grow at a CAGR of 5.85% during the period 2017-2021.

Dallas, United States - May 2, 2017 /MarketersMedia/ —

Neuropathic pain is a complex, chronic pain condition that is accompanied by tissue injury. In neuropathic pain, the nerve fibers may be damaged, dysfunctional, or injured. These nerve fibers send incorrect signals to other pain centers. The impact of nerve fiber injury creates a change in nerve function at the site of injury and areas surrounding the injury.

The report covers the present scenario and the growth prospects of the global neuropathy pain treatment market for 2017-2021. To calculate the market size, the report considers the indications of neuropathic pain such as diabetic neuropathy, chemotherapy-induced neuropathy pain, postherpetic neuralgia, and others.

Read more details of the report at Orbis Research

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Research report, Global Neuropathy Pain Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Request sample copy of the report at: http://www.orbisresearch.com/contacts/request-sample/241277

Key vendors

Depomed
Eli Lilly
Endo International
Pfizer

Other prominent vendors

Allodynic Therapeutics
Arbor Pharmaceuticals
Astellas Pharma
Aurobindo Pharma
Avanir Pharmaceuticals
Biogen
CAPNIA
Centrexion Therapeutics
Cerecor
ContraVir Pharmaceuticals
Crescita Therapeutics
DAEWOONG
Daiichi Sankyo
Dr. Reddy's Laboratories
Eisai Pharmaceuticals
Grünenthal
GlaxoSmithKline
Hydra Biosciences
Immune Pharmaceuticals
Jiangsu Hengrui Medicine
Lexicon Pharmaceuticals
Lupin
Mallinckrodt
Midatech Pharma
Neurotune
Newron Pharmaceuticals
Novaremed
Novartis
PledPharma
Premier Biomedical
Regeneron
Samyang Biopharmaceuticals
Sienna Biopharmaceuticals
Sun Pharma
Teva Pharmaceutical Industries
TheraVasc
TORAY INDUSTRIES
Torrent Pharmaceuticals
UCB Pharma
VanWorld Pharmaceutical (a subsidiary of Vanway)
VistaGen Therapeutics
WEX Pharmaceuticals
WINSTON PHARMACEUTICALS
Wockhardt
Yuhan Corporation

Market driver
Focus toward the development of novel therapeutics for postherpetic neuralgia.
For a full, detailed list, view our report

Market challenge
High unmet needs in the treatment of neuropathic pain affects the adoption rates.
For a full, detailed list, view our report

Market trend
Increasing mergers and acquisitions would lead to further consolidation.
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

Companies Mentioned:
Depomed, Eli Lilly, Endo International, Pfizer, Allodynic Therapeutics, Arbor Pharmaceuticals, Astellas Pharma, Aurobindo Pharma, Avanir Pharmaceuticals, Biogen, CAPNIA, Centrexion Therapeutics, Cerecor, ContraVir Pharmaceuticals, Crescita Therapeutics, DAEWOONG, Daiichi Sankyo, Dr. Reddy's Laboratories, Eisai Pharmaceuticals, Grünenthal, GlaxoSmithKline, Hydra Biosciences, Immune Pharmaceuticals, Jiangsu Hengrui Medicine, Lexicon Pharmaceuticals, Lupin, Mallinckrodt, Midatech Pharma, Neurotune, Newron Pharmaceuticals, Novaremed, Novartis, PledPharma, Premier Biomedical, Regeneron, Samyang Biopharmaceuticals, Sienna Biopharmaceuticals, Sun Pharma, Teva Pharmaceutical Industries, TheraVasc, TORAY INDUSTRIES, Torrent Pharmaceuticals, UCB Pharma, VanWorld Pharmaceutical (a subsidiary of Vanway), VistaGen Therapeutics, WEX Pharmaceuticals, WINSTON PHARMACEUTICALS, Wockhardt, and Yuhan Corporation.

Enquire more details of the report at: http://www.orbisresearch.com/contact/purchase/241277

About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Info:
Name: Hector Costello
Email: [email protected]
Organization: Orbis Research
Address: 4144N Central Expressway, Suite 600, Dallas, Texas - 75204, U.S.A.
Phone: +1 (214) 884-6817

Source URL: http://marketersmedia.com/neuropathy-pain-treatment-industry-increasing-mergers-and-acquisitions-would-lead-to-further-consolidation/192700

For more information, please visit http://www.orbisresearch.com/reports/index/global-neuropathy-pain-treatment-market-2017-2021

Source: MarketersMedia

Release ID: 192700